|Bid||11.76 x 1100|
|Ask||11.80 x 1800|
|Day's range||11.34 - 11.88|
|52-week range||4.34 - 18.40|
|Beta (5Y monthly)||-0.40|
|PE ratio (TTM)||N/A|
|Earnings date||11 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Apr 2014|
|1y target est||34.00|
A couple of stocks that are doing exceptionally well this year are Veru (NASDAQ: VERU) and Chevron (NYSE: CVX). Pharmaceutical company Veru has been among the hottest stocks to own this year, having more than doubled in value while the S&P 500 is firmly in negative territory, down 13%. The company and its investors are hoping that the Food and Drug Administration (FDA) grants it Emergency Use Authorization (EUA) as phase 3 trials have shown it is effective in reducing the risk of death among hospitalized patients.
Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
In the latest trading session, Veru Inc. (VERU) closed at $12.10, marking a -0.9% move from the previous day.